These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Thrombocytopenia associated with gold therapy. Observations on the mechanism of platelet destruction. Levin HA; McMillan R; Tavassoli M; Longmire RL; Yelenosky R; Sacks PV Am J Med; 1975 Aug; 59(2):274-80. PubMed ID: 808125 [TBL] [Abstract][Full Text] [Related]
43. Immunological studies in a case of gold salt induced thrombocytopenia. Stavem P; Stromme J; Bull O Scand J Haematol; 1968; 5(4):271-7. PubMed ID: 5662841 [No Abstract] [Full Text] [Related]
44. Clinical significance of positive platelet immunofluorescence test in thrombocytopenia. von dem Borne AE; Vos JJ; van der Lelie J; Bossers B; van Dalen CM Br J Haematol; 1986 Dec; 64(4):767-76. PubMed ID: 3099828 [TBL] [Abstract][Full Text] [Related]
45. Beneficial effect of intravenous gammaglobulin in a patient with complement-mediated autoimmune thrombocytopenia due to IgM-anti-platelet antibodies. Brand A; Witvliet M; Claas FH; Eernisse JG Br J Haematol; 1988 Aug; 69(4):507-11. PubMed ID: 3408686 [TBL] [Abstract][Full Text] [Related]
46. Minimal change nephropathy during gold treatment. A case with unusual histopathological and immunopathological features. Wolters J; Frederik P; van Rie H; Zeppenfeldt E Neth J Med; 1987 Dec; 31(5-6):234-40. PubMed ID: 3124008 [No Abstract] [Full Text] [Related]
49. Association of HLA-B35 with mucocutaneous lesions in Israeli patients with rheumatoid arthritis receiving gold treatment. Tishler M; Caspi D; Gazit E; Yaron M Ann Rheum Dis; 1988 Mar; 47(3):215-7. PubMed ID: 2965554 [TBL] [Abstract][Full Text] [Related]
50. Oral gold approved for some arthritis patients. FDA Drug Bull; 1985 Aug; 15(2):15-6. PubMed ID: 3932112 [No Abstract] [Full Text] [Related]
51. Gold-induced thrombocytopenia. Canada AT Am J Hosp Pharm; 1973 Apr; 30(4):340-2. PubMed ID: 4697658 [No Abstract] [Full Text] [Related]
52. Two patients with acute thrombocytopenia following gold administration and five-year follow-up. Levin MD; van t Veer MB; de Veld JC; Markusse HM Neth J Med; 2003 Jun; 61(6):223-5. PubMed ID: 13677318 [TBL] [Abstract][Full Text] [Related]
53. Comparative toxicity of gold preparations in treatment of rheumatoid arthritis. Lawrence JS Ann Rheum Dis; 1976 Apr; 35(2):171-3. PubMed ID: 821403 [TBL] [Abstract][Full Text] [Related]
54. Thrombocytopenia associated with auranofin therapy: evidence for a gold-dependent immunologic mechanism. Kosty MP; Hench PK; Tani P; McMillan R Am J Hematol; 1989 Apr; 30(4):236-9. PubMed ID: 2929583 [TBL] [Abstract][Full Text] [Related]
55. Regression of autoimmune thrombocytopenia after eradication of Helicobacter pylori. Gasbarrini A; Franceschi F; Tartaglione R; Landolfi R; Pola P; Gasbarrini G Lancet; 1998 Sep; 352(9131):878. PubMed ID: 9742983 [No Abstract] [Full Text] [Related]
57. [The therapeutic procedure in autoimmune thrombocytopenia in relation to the immunoglobulin specificity of the antithrombocytic autoantibodies]. Tishchenko LM Vrach Delo; 1990 Jul; (7):82-6. PubMed ID: 2238609 [TBL] [Abstract][Full Text] [Related]
58. Immunoglobulin M antiplatelet autoantibodies from mice immunized with rat platelets induce thrombocytopenia and platelet function impairment. Detalle L; Su D; van Rooijen N; Coutelier JP Exp Biol Med (Maywood); 2010 Dec; 235(12):1464-71. PubMed ID: 21127343 [TBL] [Abstract][Full Text] [Related]